Eyenuk Launches EyeScreen Human + AI Diagnostic Service

By

NEW YORK—Eyenuk, Inc., an artificial intelligence (AI) medical technology and services company, is launching the EyeScreen Human + AI Diagnostic Service for diabetic retinopathy (DR). By combining the high accuracy of AI disease detection with the accepted practice of human grading, the EyeScreen Service is designed to improve the overall safety of the system in contrast to other tele-retinal screening services that only use human grading.

The EyeScreen Human + AI Diagnostic Service connects primary care/diabetes care clinics with eyecare specialists and is designed to increase access to diabetic retinopathy screening, reduce wait times, and improve patient compliance on receiving necessary screenings. By offering DR screening in clinic, physicians can identify silently progressing diabetic retinopathy sooner and begin intervention faster, thus improving patient outcomes and reducing the incidence of vision loss due to DR.

Increased patient compliance and more screenings can lead to improved Healthcare Effectiveness Data and Information Set (HEDIS) measures and Centers for Medicare & Medicaid Services (CMS) Five-Star Quality Ratings. The EyeScreen Human + AI Diagnostic Service provides an actionable, easy-to-read ICD-10 compliant report allowing seamless documentation and is reimbursable under existing CPT codes.


The EyeScreen service utilizes independent, unbiased interpretation by a human expert and a validated autonomous AI system that does not rely on humans interpreting complex assistive AI reports. After the retinal images are independently assessed by both the AI disease detection system and specialist human graders separately, an ICD-10 compliant report is sent to the physician. In the event that the AI and human graders disagree, the images are adjudicated by another highly experienced human expert.